Company: EDSA
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001171843-25-003189
Chunk: 74

Company: Edesa Biotech, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 74
---
93

			$
			18.33

			Expired

			(374
			)

			246.96

			246.96

			Balance - March 31, 2025

			382,666

			$
			24.66

			$
			18.10

			Six Months Ended March 31, 2024

			Balance - September 30, 2023

			420,615

			$
			25.60

			$
			18.84

			Granted

			500

			4.10

			3.10

			Forfeited

			(1,333
			)

			15.55

			11.08

			Expired

			(106
			)

			596.82

			596.82

			Balance - March 31, 2024

			419,676

			$
			25.47

			$
			18.70

During the three and six months ended March 31, 2025, there were no employee or director options granted. During the three and six months ended March 31, 2024, there were 500 employee options granted and no director options granted. The options have a term of 10 years and an exercise price equal to the Nasdaq closing price on the grant date.

The weighted average contractual life remaining on the outstanding options at March 31, 2025 is 74 months.

The following table summarizes information about the options under the 2019 Plan outstanding and exercisable at March 31, 2025:

			Number of Options (#) 

			Exercisable at 
			March 31, 2025 (#)  

			Range of Exercise Prices 

			Expiry Dates

			 37,719

			 37,719

			C$
			
			15.12

			August 2027 - Dec 2028

			 43,031

			 43,031

			$
			
			22.12

			Feb 2030

			 51,006

			 51,006

			$
			
			52.08 - 56.49 

			September 2030 - Oct 2030

			 81,041

			 81,041